Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Patients on Tenofovir therapy: Relevance for Screening Strategies

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Impaired cerebral microcirculation induced by ammonium chloride in rats is due to cortical adenosine release

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Micro-elimination - A path to global elimination of hepatitis C

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Reply to: "High volume plasma exchange in patients with acute liver failure"

    Research output: Contribution to journalComment/debateResearchpeer-review

  5. Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Gilles Wandeler
  • Etienne Mauron
  • Andrew Atkinson
  • Jean-François Dufour
  • David Kraus
  • Peter Reiss
  • Lars Peters
  • François Dabis
  • Jan Fehr
  • Enos Bernasconi
  • Marc van der Valk
  • Colette Smit
  • Lars K Gjærde
  • Jürgen Rockstroh
  • Didier Neau
  • Fabrice Bonnet
  • Andri Rauch
  • Swiss HIV Cohort Study, Athena Observational Cohort Study, EuroSIDA, ANRS CO3 Aquitaine Cohort
View graph of relations

BACKGROUND & AIMS: Robust data on hepatocellular carcinoma (HCC) incidence among HIV/hepatitis B virus (HBV)-coinfected individuals on antiretroviral therapy (ART) are needed to inform HCC screening strategies. We aimed to evaluate the incidence and risk factors of HCC among HIV/HBV-coinfected individuals on tenofovir disoproxil fumarate (TDF)-containing ART in a large multi-cohort study.

METHODS: We included all HIV-infected adults with a positive hepatitis B surface antigen test followed in 4 prospective European cohorts. The primary outcome was the occurrence of HCC. Demographic and clinical information was retrieved from routinely collected data, and liver cirrhosis was defined according to results from liver biopsy or non-invasive measurements. Multivariable Poisson regression was used to assess HCC risk factors.

RESULTS: A total of 3,625 HIV/HBV-coinfected patients were included, of whom 72% had started TDF-containing ART. Over 32,673 patient-years (py), 60 individuals (1.7%) developed an HCC. The incidence of HCC remained stable over time among individuals on TDF, whereas it increased steadily among those not on TDF. Among individuals on TDF, the incidence of HCC was 5.9 per 1,000 py (95% CI 3.60-9.10) in cirrhotics and 1.17 per 1,000 py (0.56-2.14) among non-cirrhotics. Age at initiation of TDF (adjusted incidence rate ratio per 10-year increase: 2.2, 95% CI 1.6-3.0) and the presence of liver cirrhosis (4.5, 2.3-8.9) were predictors of HCC. Among non-cirrhotic individuals, the incidence of HCC was only above the commonly used screening threshold of 2 cases per 1,000 py in patients aged >45 years old at TDF initiation.

CONCLUSIONS: Whereas the incidence of HCC was high in cirrhotic HIV/HBV-coinfected individuals, it remained below the HCC screening threshold in patients without cirrhosis who started TDF aged <46 years old.

LAY SUMMARY: We investigated the incidence of hepatocellular carcinoma in HIV/hepatitis B virus-coinfected individuals from a large multi-cohort study in Europe. Over 32,673 patient-years, 60 individuals (1.7%) developed hepatocellular carcinoma. The incidence of hepatocellular carcinoma remained low in patients without cirrhosis, who started on tenofovir disoproxil fumarate when aged <46 years old.

Original languageEnglish
JournalJournal of Hepatology
Volume71
Issue number2
Pages (from-to)274-280
Number of pages7
ISSN0168-8278
DOIs
Publication statusPublished - 2019

Bibliographical note

Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

    Research areas

  • Antiretroviral, Hepatitis B infection, Hepatocellular carcinoma, HIV infection, Nucleotide inhibitors, Screening, Surveillance

ID: 57116548